Who are alpha blocker monotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levobupivacaine with epinephrine, Xylocaine with Epinephrine, Buffered Articaine Hydrochloride + Epinephrine, Articaine Hydrochloride + Epinephrine, Entecavir+Carvedilol, Eye injection (Mydrane).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha-blocker-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

alpha blocker monotherapy — Competitive Intelligence Brief

alpha blocker monotherapy (alpha blocker monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha blocker. Area: Cardiovascular.

marketed Alpha blocker alpha-1 adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

alpha blocker monotherapy (alpha blocker monotherapy) — Samsung Medical Center.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
alpha blocker monotherapy TARGET	alpha blocker monotherapy	Samsung Medical Center	marketed	Alpha blocker	alpha-1 adrenergic receptors
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Xylocaine with Epinephrine	Xylocaine with Epinephrine	Vrije Universiteit Brussel	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Entecavir+Carvedilol	Entecavir+Carvedilol	ShuGuang Hospital	marketed	Antiviral + Beta-blocker combination	HBV reverse transcriptase; beta-1, beta-2, and alpha-1 adrenergic receptors
Eye injection (Mydrane)	Eye injection (Mydrane)	Medical University of Graz	marketed	Ophthalmic combination agent (mydriatic + anesthetic)	Muscarinic acetylcholine receptors (tropicamide); alpha-1 adrenergic receptors (phenylephrine); sodium channels (lidocaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha blocker class)

Assaf-Harofeh Medical Center · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). alpha blocker monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha-blocker-monotherapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab